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Abstract
This study was prospectively conducted in 11 haematology divi-
sions over a 2-year period to evaluate the efﬁcacy of caspofungin
in 24 neutropenic patients with haematological malignancies (HM)
and candidaemia. These patients had received chemotherapy for
HM and were neutropenic (PNN < 0.5 · 109/L) for a median of
12 days (2–41) before candidaemia. The patients received caspo-
fungin for a median duration of 12 days (range 6–26), obtaining a
favourable overall response of 58%. At 30 days, 11 patients had
died (46%); candidaemia was responsible for mortality in six
patients (25%). These results suggest that treatment of candida-
emia with caspofungin in neutropenic HM was efﬁcacious, as it is
in non-haematological subgroups.
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Fungal infections are the major cause of morbidity and mor-
tality in patients with haematological malignancies (HM).
Among yeast infections, those due to Candida spp., although
in decline, remain one of the most frequent complications in
neutropenic patients, and candidaemia is characterized by a
high mortality rate, ranging between 30 and 40% [1–3]. In
recent years, several randomized, double-blind, multicentre
studies have been performed to evaluate the efﬁcacy of
newer antifungal drugs in cases of candidaemia and other
forms of invasive candidiasis [4–9].
In these trials, neutropenic patients were either excluded
or represented by only a small proportion of the cohort,
making it difﬁcult to reach the same level of certainty as that
concerning non-neutropenic patients. In the present multi-
centre prospective trial we studied the clinical course and
outcome of 24 neutropenic patients with candidaemia who
were treated with caspofungin during a 2-year period.
Neutropenic patients (absolute neutrophil count of
<0.5 · 109/L) with an underlying HM and candidaemia were
included in the study. Exclusion criteria were allergy or any
serious reaction to echinocandin, previously chronic candidi-
asis, candidaemia within the previous month, a diagnosis of
chronic or acute hepatitis or cirrhosis, expected survival
<5 days, or empirical antifungal therapy for >3 days before
caspofungin treatment. Consent was requested and one
patient refused to participate.
Efﬁcacy was assessed according to the new EORTC/MSG
criteria [10]. The outcome was considered unfavourable if
infection was clinically or microbiologically unresponsive, if
there was a relapse during the 4–8-week follow-up period,
or if the study drug was withdrawn due to toxic effects that
necessitated a change in antifungal therapy. Mortality attrib-
utable to Candida was considered when patients died with
microbiological, histological or clinical evidence of active
fungal infection.
During the study period (January 2005 to December
2007) 38 new diagnoses of candidaemia were noted at 11
participating centres. Twelve patients (31.5%) were excluded
for the following causes: late diagnosis and empirical antifun-
gal therapy (other than caspofungin) for >3 days before diag-
nosis (n = 6), post-mortem diagnosis of candidaemia (n = 4),
severe hepatic insufﬁciency (n = 1) and refusal to participate
in the study (n = 1). Of the remaining 26 patients (68%), two
were excluded from the analysis because they were not neu-
tropenic at diagnosis of candidaemia. Demographical and clin-
ical characteristics, risk factors and symptoms of the 24
evaluable patients are shown in Table 1.
In all patients, candidaemia developed during the aplasia
period following chemotherapy. Notably, infection occurred
after a haematopoietic stem cell transplantation procedure in
11 patients. Only nine patients (37%) had been receiving
anti-fungal prophylaxis (ﬂuconazole, ﬁve; itraconazole, two;
voriconazole, two). Fever was present in all patients and
diagnosis of candidaemia was made after a median time of
3 days (range 1–12) from onset of fever.
Patients received caspofungin at a dose of 50 mg/day,
after a 70-mg loading dose on day 1. In four patients with
C. parapsilosis candidaemia, caspofungin dosage was increased
to 70 mg every day per protocol. Patients were treated for
a median of 12 days (range 6–26). In all patients, according
to protocol, the CVC was removed upon diagnosis of candi-
daemia. No drug-related adverse event was noted in any
patient. There was a favourable overall response to therapy
in 58% of patients (14/24). Persistent infection was docu-
mented in ten patients (four, C. albicans; three, C. parapsilosis;
two, C. tropicalis; one C. dubliniensis), who demonstrated a
worsened clinical condition that was associated with positive
TABLE 1. Principal ﬁndings concerning enrolled patients
Patients, n (M/F) 24 (16/8)
Median age (range) 52 y.o. (range 19–71)
Underlying haematological disease
AML 11 (46%)
ALL 3 (12.5%)
NHL 7 (29%)
MM 2 (8%)
CLL 1 (4%)
Haematopoietic stem cell transplantation procedures 11 (46%)
Allogeneic 7 (29%)
Autologous 4 (17%)
At onset of candidaemia
Neutropenic pts
(ANC < 0.5 · 109/L) 24 (100%)
(ANC < 0.1 · 109/L) 13 (54%)
Other risk factors (%)
CVC 18 (75%)
Steroid administration 12 (50%)
Mucositis 19 (79%)
Candida colonization 13 (54%)
Diabetes 3 (13%)
Clinical manifestations
Fever 24 (100%)
Dyspnoea 8 (33%)
Diarrhoea 6 (25%)
Hepatosplenic abscesses 4 (17%)
Set of blood samples positive for Candida spp. (n)
1 7 episodes (29%)
2–4 14 episodes (58%)
>5 7 episodes (29%)
Candida isolatesa
C. albicans 11 (46%)
C. parapsilosis 4 (17%)
C. krusei 3 (12.5%)
C. tropicalis 2 (8%)
C. famata 1 (4%)
C. lusitanae 1 (4%)
C. guillermondii 1 (4%)
C. dubliniensis 1 (4%)
Complete response to caspofungin therapy 14 (58%)
Crude mortality at 30 days from candidaemia onset 11 (46%)
Death from candidaemia 6 (25%b)
Death from HM 5 (21%)
AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; NHL,
non-Hodgkin lymphoma; MM, multiple myeloma; CLL, chronic lymphocytic
leukaemia; HM, haematological malignancies.
aNone of the isolated strains was resistant to caspofungin in vitro. Antifungal sus-
ceptibility testing of Candida isolates was performed by the CLSI-M27-A2 broth
microdilution method [13].
bMortality attributable to candidaemia.
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culture results at days 7 (n = 5) and 14 (n = 3) after the ﬁrst
candidaemia. The 30-day overall mortality rate was 46% (11/
24). Candidaemia was considered responsible in six patients
(25%). Among the remaining ﬁve patients who died, three
died from HM progression and two from haemorrhage.
Using multivariate and univariate analyses, no factors inﬂu-
encing complete response to treatment were identiﬁed.
Recent studies have suggested that Candida remains the
predominant pathogen among yeast complications [1].
Despite reduced frequency and the development of new,
more effective antifungal drugs, candidaemia mortality rates
remains high, ranging from 25 to 40% [4–9]. In the new
IDSA guidelines for treatment of neutropenic patients, an
echinocandin or a lipid formulation of amphotericin-B is sug-
gested for most patients if the Candida spp. is unknown, with
ﬂuconazole as an alternative for less-critically ill patients who
have no recent exposure to an azole [11].
No adequately powered randomized controlled trial con-
cerning treatment of candidaemia in neutropenic patients has
been reported. In various randomized double-blind multicen-
tre studies, few patients indeed had neutropenia at baseline,
thus making it difﬁcult to draw meaningful conclusions about
the efﬁcacy of the different antifungal drugs in such patients
[4–9]. This reﬂects the difﬁculty encountered when enrolling
patients, in most cases due to a lapse of time required to
establish the diagnosis longer than the maximum duration of
empiric antifungal therapy according to protocol criteria. In
the present trial, 31.5% of the potential patients were
excluded from enrolment because of neutropenia.
The efﬁcacy of caspofungin in the treatment of invasive
candidiasis in these patients was evaluated through a retro-
spective, post hoc review of three completed studies within
the Merck database, including 25 patients with candidaemia.
A favourable response was noted in 68% of cases [12].
In other studies analysing the efﬁcacy of different antifun-
gal agents, a total of 171 neutropenic patients were included,
with a favourable overall response of 60% (103/171) [4–9].
We obtained a complete response, comparable to that
reported in neutropenic patients enrolled in these studies
using different antifungal drugs or caspofungin. Notably,
despite the small number of patients enrolled in our series,
the response rate was similar to the overall response
obtained in trials using caspofungin in non-neutropenic
patients, regardless of the species of Candida, and our results
indicate that caspofungin could be a safe and equally effective
treatment for candidaemia in HM neutropenic patients, as
already demonstrated for non-neutropenic patients, without
signiﬁcant differences in species-related outcome. Larger per-
spective studies of candidaemia in this subset of patients,
although warranted, are in our opinion not easy to carry out
because of the reduction of the incidence of candidaemia in
HM and the diagnostic difﬁculties that remain.
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